You are here: Home » Markets » News
Business Standard

Sun Pharma inches up on signing pact to develop nervous system drugs

The stock opened at Rs 759 and touched an intraday high of Rs 766 on the BSE

SI Reporter  |  Mumbai 

Sun Pharma inches up on signing pact to develop nervous system drugs

Shares of Sun Pharma are up almost 1% at Rs 763 in a subdued market after the drug maker announced that it has entered into an agreement with Israel based Weizmann Institute of Science and Spain's Health Research Institute of Santiago de Compostela to develop products for treating neurological diseases like brain stroke and glioblastoma, a lethal brain cancer.

Scientists at Weizmann Institute have developed a recombinant enzyme currently undergoing animal studies for indications of brain stroke and glioblastoma.

Further studies of this enzyme will be conducted at the Health Research Institute of Santiago de Compostela in Spain. CLICK HERE FOR FULL STORY

The stock opened at Rs 759 and touched an intraday high of Rs 766 on the BSE. At 10:20 am, around 600,000 shares were traded on both the stock exchanges.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, December 11 2015. 10:23 IST
RECOMMENDED FOR YOU
.